TITLE

Another PML Case: Raptiva is Implicated

PUB. DATE
October 2008
SOURCE
Bioworld Week;10/13/2008, Vol. 16 Issue 41, p2
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on the alert case warning by Genentech Inc. regarding a rare life-threatening brain infection in an elderly patient treated with Raptiva. It is stated that viral infection known as progressive multifocal leukoencephalopathy (PML) was seen in a 70-year old U.S. male patient who had received Raptiva for more than four years to treat chronic plaque psoriasis. However, the U.S. Food and Drug Authority (FDA) updated the prescribing information for Raptiva.
ACCESSION #
34835723

 

Related Articles

  • Raptiva Off and Running. Troy, Timothy N. // Dermatology Times;Dec2003, Vol. 24 Issue 12, p18 

    Reports on research on the use of the drug Raptiva (efalizumab) in the treatment of moderate to severe plaque psoriasis. Significant reduction in signs and symptoms following 12 weeks of treatment; Continued benefits after 24 weeks of treatment; U.S. Food and Drug Administration approval for...

  • 3 PML Deaths Confirmed in Raptiva Patients.  // Bioworld Week;2/23/2009, Vol. 17 Issue 8, p4 

    The article reports on the public health advisory of the FDA concerning the development of brain infection progressive multifocal leukoencephalopathy (PML) in patients taking Genentech Inc.'s Raptiva. FDA notes that none of the patients were receiving other treatments while taking Raptiva. Also,...

  • 3 PML Deaths Confirmed in Raptiva Patients. Young, Donna // BioWorld Today;2/20/2009, Vol. 20 Issue 33, p3 

    The article reports on a public health advisory issued by the U.S. Food & Drug Administration about three confirmed cases and possibly a fourth of the brain infection progressive multifocal leukoencephalopathy (PML) in patients using Raptiva drug from Genentech Inc. According to regulators, two...

  • RIP Raptiva? DeFrancesco, Laura // Nature Biotechnology;Apr2009, Vol. 27 Issue 4, p303 

    The article reports that the U.S. Food and Drug Administration has issued a public health advisory on the psoriasis drug Raptiva, which is marketed by Genentech. This comes after there have been four cases and three confirmed deaths from progressive multifocal leukoencephalopathy (PML), a rare...

  • NEWS brief.  // Dermatology Times;Mar2009, Vol. 30 Issue 3, p34 

    This section offers news briefs related to health and medicine as of March 2009. A public health advisory has been issued by the U.S. Food and Drug Administration (FDA) for the psoriasis drug Raptiva (efalizumab) from Genentech. A device is being developed for skin cancer detection without a...

  • Raptiva rounds hot corner, heads for hotter market.  // Dermatology Times;Oct2003, Vol. 24 Issue 10, p92 

    Reports on the recommendation from the U.S. Food and Drug Administration advisory panel of Raptiva, a drug use to treat psoriasis from Genentech Inc. Planned launching of the drug; Testing of the drug; Efficacy of the drug.

  • MEDWATCH: Company Recalls Psoriasis Drug, FDA Issues Warning on Skin Patches.  // American Family Physician;5/1/2009, Vol. 79 Issue 9, p734 

    The article reports on the decision of Genentech to recall Raptiva, a drug for psoriasis, from the U.S. market. It notes that patients who take the drug are at risk of developing progressive multifocal leukoencephalopathy, a progressive neurologic disease. It also mentions that the Food and Drug...

  • RARE BRAIN INFECTION CONFIRMED IN PATIENTS ON EFALIZUMAB.  // Dermatology Times;Mar2009, Vol. 30 Issue 3, p32 

    The article offers information on a public health advisory issued by the U.S. Food and Drug Administration (FDA) on February 19, 2009 which revealed three cases of progressive multifocal leukoencephalopathy (PML) in patients taking the psoriasis drug efalizumab (Raptiva). According to FDA, a...

  • WEEK IN WASHINGTON.  // BioWorld Insight;12/20/2010, Vol. 18 Issue 51, p6 

    The article reports that the U.S. Food & Drug Administration (FDA) intends to strike the HER2-negative metastatic breast cancer indication from Genentech Inc./Roche AG's Avastin and issued a new draft guidance document for drugmakers to develop and examine two or more investigational medicines.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics